News & insights
FDA
Articles from Apotek Analytics.
-

US loses measles elimination status while Isomorphic raises record $5bn
Global health authorities said the United States has lost its measles elimination status after several states faced their worst outbreaks in nearly three decades, and the CDC and partners set out plans to stop the outbreaks and restore it.
-

GLP-1 Drugs may risk investments in other essential treatments
Diabetes care in poorer settings drew attention from two directions.
-

FDA tentatively approves first generic lenacapavir. Zolgensma tumour cases shake gene therapy
HIV prevention moved closer to reach in poorer countries as the FDA gave tentative approval to the first generic lenacapavir.
-

Lilly’s retatrutide beats Ozempic. Artiva drops its autoimmune cell therapy after two trial deaths
Eli Lilly’s ‘triple-G’ drug retatrutide beat Novo Nordisk’s Ozempic on blood sugar and weight loss in a head-to-head phase 3 trial in type 2 diabetes, though with more side effects and treatment discontinuations.
-

FDA approves GSK and Ionis hepatitis B drug that offers some patients a functional cure
The FDA approved bepirovirsen, a first of its kind antisense injection for chronic hepatitis B from GSK and Ionis, as dealmaking led the rest of the week’s coverage.
-

Pfizer, Roche and AstraZeneca lead a week of drug discovery deals
Pfizer, Roche and AstraZeneca each struck discovery deals reported at $500m or more, as regulators in the UK, US and Europe signalled changes in how they weigh evidence.
-

AI puts the ultrasound probe in more hands as histotripsy reaches a $3.75bn valuation
AI guidance is putting the ultrasound probe in more hands, the major vendors have refreshed their ranges and histotripsy has reached a $3.75bn valuation.